1. Ticagrelor led to a smaller 30-day cardiac magnetic resonance (CMR)-defined infarct size than clopidogrel in pharmaco-invasive STEMI Evidence Rating ...
Concomitant use of direct oral anticoagulants and interacting antiarrhythmic drugs and the risk of stroke and bleeding among patients with ...
1. At one month, ticagrelor was not superior to twice-daily clopidogrel in reducing major adverse cardiovascular events (MACEs) in adult ...
Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes 1. In patients with type 2 diabetes (T2D), ...
1. In this systematic review and meta-analysis, de-escalating dual antiplatelet therapy to ticagrelor monotherapy following implantation of a drug-eluting stent ...
1. Ticagrelor was non-inferior to DAPT for the incidence of major adverse cardiovascular and cerebrovascular events. 2. Ticagrelor monotherapy significantly ...
1. Clinically relevant bleeding was significantly lower with ticagrelor monotherapy than in the ticagrelor plus aspirin group. 2. Major cardiovascular ...
1. Clinically relevant bleeding was significantly lower with ticagrelor monotherapy than in the ticagrelor plus aspirin group. 2. Major cardiovascular ...
1. Patients carrying the CYP2C19 loss-of-function mutation (C-LOF), who had experienced a minor stroke or transient ischemic attack, experienced a ...
1. Treatment after a minor stroke or transient ischemic attack with dual anti-platelet therapy (DAPT), either clopidogrel with aspirin or ...
